News

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...
BioSpace3d

Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...
Fierce Pharma2d

Biogen raises sales outlook as Leqembi awaits FDA decision on new dosing option

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...
KTLA2mon

Eisai projects Leqembi® revenue to total JPY 76.5 billion for ... - KTLA

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...
BioSpace2d

Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
KELOLAND News2mon

Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...
Morningstar2mon

Eisai projects Leqembi® revenue to total JPY 76.5 ... - Morningstar

Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) Provided by PR Newswire May 15, 2025, 1:56:00 AM ...